TYSABRI (Biogen Inc.)
Welcome to the PulseAid listing for the TYSABRI drug offered from Biogen Inc.. This Integrin Receptor Antagonist [EPC],Integrin Receptor Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Biogen Inc. |
| NON-PROPRIETARY NAME: | natalizumab |
| SUBSTANCE NAME: | NATALIZUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Integrin Receptor Antagonist [EPC],Integrin Receptor Antagonists [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2004-11-23 |
| END MARKETING DATE: | 0000-00-00 |
TYSABRI HUMAN PRESCRIPTION DRUG Details:
| Item Description | TYSABRI from Biogen Inc. |
| LABELER NAME: | Biogen Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 300(mg/15mL) |
| START MARKETING DATE: | 2004-11-23 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 64406-008_394e6153-238c-41b3-a8ae-6d0e7614dde6 |
| PRODUCT NDC: | 64406-008 |
| APPLICATION NUMBER: | BLA125104 |
Other NATALIZUMAB Pharmaceutical Manufacturers / Labelers:
